Publications

2024 cardiometabolic

Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial.

EUROPEAN JOURNAL HEART FAILURE

2024; 27(2): 347-352.

2024 cardiometabolic

Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF).

JACC HEART FAILURE

2024; 12(11): 1830-1841.

2023 cardiometabolic

Examining the Burden of Potentially Avoidable Heart Failure Hospitalizations

CLINICOECONOMICS AND OUTCOMES RESEARCH

2023; Sep 29;15: 721-731.

2023 cardiometabolic

A novel opportunity to improve heart failure care: focusing on subcutaneous furosemide

Heart Failure Reviews

July 13, 2023, Volume 28 Pages 1315–1323

2023 orphan lung

Inhaled, Nebulized Clofazimine for the Treatment of Pulmonary Nontuberculous Mycobacteria Disease Offers the Prospect of Convenient Dosing and Prolonged Activity

JOURNAL OF INFECTIOUS DISEASES & THERAPY

2023; 4(11)

2023 orphan lung

Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection

Antimicrobial Agents and Chemotherapy

2023; 2(67)

2023 cardiometabolic

Descriptive Epidemiology and Outcomes of Patients with Short Stay Hospitalizations for the Treatment of Congestive Heart Failure in the US

ClinicoEconomics and Outcomes Research

February 24, 2023, Volume 15 Pages 139–149

2023 cardiometabolic

Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study.

FUTURE CARDIOLOGY

2023; 19(8): 385-396.

2023 cardiometabolic

Time–Action Profile of Technosphere Insulin in Children with Type 1 Diabetes

DIABETES THERAPY

2023; 14(3): 611-617

2022 cardiometabolic

From Oral to Subcutaneous Furosemide: The Road to Novel Opportunities to Manage Congestion.

STRUCTURAL HEART

2022; Aug 7; 6(4): 100076.

2022 cardiometabolic

Evaluation of a Weekly Physician-Driven Bolus Titration Algorithm in Patients with Type 2 Diabetes Prescribed V-Go® Wearable Insulin Delivery Device for Basal-Bolus Therapy

Annals of Diabetes, Metabolic Disorders & Control

2022; 3(1): 120

2021 cardiometabolic

Ultra Rapid-Acting Inhaled Insulin Improves Glucose Control in Patients With Type 2 Diabetes Mellitus

Endocrine Practice

2021; 27(5): 449-454

Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial.

Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF).

Examining the Burden of Potentially Avoidable Heart Failure Hospitalizations

A novel opportunity to improve heart failure care: focusing on subcutaneous furosemide

Inhaled, Nebulized Clofazimine for the Treatment of Pulmonary Nontuberculous Mycobacteria Disease Offers the Prospect of Convenient Dosing and Prolonged Activity

Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection

Descriptive Epidemiology and Outcomes of Patients with Short Stay Hospitalizations for the Treatment of Congestive Heart Failure in the US

Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study.

Time–Action Profile of Technosphere Insulin in Children with Type 1 Diabetes

From Oral to Subcutaneous Furosemide: The Road to Novel Opportunities to Manage Congestion.

Evaluation of a Weekly Physician-Driven Bolus Titration Algorithm in Patients with Type 2 Diabetes Prescribed V-Go® Wearable Insulin Delivery Device for Basal-Bolus Therapy

Ultra Rapid-Acting Inhaled Insulin Improves Glucose Control in Patients With Type 2 Diabetes Mellitus

Expanding Patient Choice in Diabetes Care: Reducing Access Barriers to Inhaled Insulin

Experiences With Inhaled Insulin in a Real-World Sample of Adults With Type 1 Diabetes in the T1D Exchange Registry

Inhaled Insulin Dosing in a Randomized Trial in Adults With Type 1 Diabetes

Inhaled Technosphere Insulin Reduces Postmeal Glucose Excursion in Youth Living with Type 1 Diabetes

Inhaled Technosphere Insulin in Children with Diabetes: The INHALE-1 Extension Study

Role of Ultra-Rapid Acting Insulin in Managing Diabetes

30 Years of Developing Inhaled Insulin

Dosing Afrezza: It's Not that Complicated

Unmet Needs in Insulin-Treated Diabetes Management

Pulmonary Safety and Clinical Considerations for Inhaled Insulin: A Comprehensive Review

Impact of Inhaled Insulin Therapy on Hypoglycemia

Potential Applications of Inhaled Insulin in Diabetic Ketoacidosis Prevention and During Exercise: Two Case Presentations

Safety and Pharmacokinetic Data for Inhaled Administration of Nintedanib Dry Powder Inhalation for Treatment of Pulmonary Fibrotic Diseases

Preclinical Studies of Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease

Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease

Inhaled, Nebulized Clofazimine for the Treatment of Pulmonary Nontuberculous Mycobacteria Disease Offers the Prospect of Convenient Dosing and Prolonged Activity

Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection

Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections

Now FDA Approved:
Furoscix ReadyFlow™

(furosemide injection)

Publications

Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial.

Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF).

Examining the Burden of Potentially Avoidable Heart Failure Hospitalizations

A novel opportunity to improve heart failure care: focusing on subcutaneous furosemide

Inhaled, Nebulized Clofazimine for the Treatment of Pulmonary Nontuberculous Mycobacteria Disease Offers the Prospect of Convenient Dosing and Prolonged Activity

Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection

Descriptive Epidemiology and Outcomes of Patients with Short Stay Hospitalizations for the Treatment of Congestive Heart Failure in the US

Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study.

Time–Action Profile of Technosphere Insulin in Children with Type 1 Diabetes

From Oral to Subcutaneous Furosemide: The Road to Novel Opportunities to Manage Congestion.

Evaluation of a Weekly Physician-Driven Bolus Titration Algorithm in Patients with Type 2 Diabetes Prescribed V-Go® Wearable Insulin Delivery Device for Basal-Bolus Therapy

Ultra Rapid-Acting Inhaled Insulin Improves Glucose Control in Patients With Type 2 Diabetes Mellitus

Expanding Patient Choice in Diabetes Care: Reducing Access Barriers to Inhaled Insulin

Experiences With Inhaled Insulin in a Real-World Sample of Adults With Type 1 Diabetes in the T1D Exchange Registry

Inhaled Insulin Dosing in a Randomized Trial in Adults With Type 1 Diabetes

Inhaled Technosphere Insulin Reduces Postmeal Glucose Excursion in Youth Living with Type 1 Diabetes

Inhaled Technosphere Insulin in Children with Diabetes: The INHALE-1 Extension Study

Role of Ultra-Rapid Acting Insulin in Managing Diabetes

30 Years of Developing Inhaled Insulin

Dosing Afrezza: It's Not that Complicated

Unmet Needs in Insulin-Treated Diabetes Management

Pulmonary Safety and Clinical Considerations for Inhaled Insulin: A Comprehensive Review

Impact of Inhaled Insulin Therapy on Hypoglycemia

Potential Applications of Inhaled Insulin in Diabetic Ketoacidosis Prevention and During Exercise: Two Case Presentations

Safety and Pharmacokinetic Data for Inhaled Administration of Nintedanib Dry Powder Inhalation for Treatment of Pulmonary Fibrotic Diseases

Preclinical Studies of Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease

Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease

Inhaled, Nebulized Clofazimine for the Treatment of Pulmonary Nontuberculous Mycobacteria Disease Offers the Prospect of Convenient Dosing and Prolonged Activity

Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection

Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections

Now FDA Approved: Furoscix ReadyFlow™

(furosemide injection)

Now FDA Approved:
Furoscix ReadyFlow™